President Donald Trump has denied reports that he is planning to fire Food and Drug Administration (FDA) Commissioner Marty Makary. Speaking to reporters outside the White House on May 8, Trump downplayed the speculation, stating, 'I've been reading about it, but I know nothing about it.' When asked directly about Makary's status, Trump responded, 'Nothing much, he’s doing fine.'
The reports of a potential ouster stem from a Wall Street Journal article suggesting Trump pressured Makary to expedite approval for flavored nicotine vapes. According to the report, Makary pushed back, leading to tensions. However, Trump did not confirm the reporting, telling reporters, 'No, no,' when asked if he was considering replacing the FDA chief.
Background on Makary's Tenure
Makary, confirmed as FDA commissioner in March 2025, has faced controversies, including accusations from pro-life activists that he delayed safety reviews for abortion pills. He has also been involved in discussions on lowering drug costs and other health policy initiatives.
Policy Disputes and Context
The reported friction between Trump and Makary centers on regulatory decisions, particularly regarding nicotine vapes. While the Wall Street Journal framed the dispute as a direct clash, other outlets, including The Epoch Times, focused on Trump’s denial of any plans to replace Makary. The differing emphases highlight the varying interpretations of the same set of events.
Political and Procedural Implications
The potential removal of an FDA commissioner is a significant administrative action, as it could signal shifts in regulatory priorities. However, Trump’s public dismissal of the reports suggests stability in the agency’s leadership, at least for the near term. The lack of confirmation from the White House leaves the underlying tensions unresolved but de-emphasized in the immediate public discourse.